Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 55.59 -0.95 (-1.68%) Market Cap: 3.47 Bil Enterprise Value: 3.14 Bil PE Ratio: 0 PB Ratio: 308.96 GF Score: 58/100

Rhythm Pharmaceuticals Inc To Discuss Hypothalamic Obesity Call Transcript

Jul 12, 2022 / 12:00PM GMT
Release Date Price: $6.67 (+42.22%)
Operator

And thank you for standing by. Welcome to the Rhythm Pharmaceuticals Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Connolly, with Rhythm Pharmaceuticals. Please go ahead.

David Connolly
Rhythm Pharmaceuticals, Inc. - Head of IR & Corporate Communications

Yes, thank you, and thank you all for joining us today. For those participating via the conference call, there are accompanying slides that can be accessed and controlled by going to the Events section of our Investors page on our website at ir.rhythmtx.com.

This morning, we announced positive interim results from our Phase II clinical trial evaluating setmelanotide in hypothalamic obesity via a press release, which is now available on our website.

On the conference call today, as listed on Slide 2 on the agenda, are Dr. David Meeker, Rhythm Chair, Chief Executive Officer and President; Dr. Jennifer Abuzzahab, a pediatric endocrinologist at the McNeely

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot